Carmen Espinosa, MD
Psychiatry · Miami, FLNPI 1154426955
Payments from drug & device makers
Across 67 payments — averaging $1932.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$59K
- Teva Pharmaceuticals USA, Inc.$48K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21K
- Otsuka America Pharmaceutical, Inc.$677
- Alkermes, Inc.$376
- Johnson & Johnson$224
- plus $284 from 3 others
Across 11 payments — averaging $69.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$760
What the payments were for
- Food & beverage$1,571100%
- Education$40%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $58,915 |
| Teva Pharmaceuticals USA, Inc. | 25 | $48,339 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $20,671 |
| Otsuka America Pharmaceutical, Inc. | 9 | $677 |
| Alkermes, Inc. | 5 | $376 |
| Johnson & Johnson | 2 | $224 |
| Neurocrine Biosciences, Inc. | 1 | $124 |
| Luye Pharma (USA) Ltd. | 1 | $122 |
| Sunovion Pharmaceuticals Inc. | 3 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$951
- REXULTI$492
- LYBALVI$456
- ARISTADA INITIO$238
- SPRAVATO$224
- INGREZZA$124
- ERZOFRI EXTENDED-RELEASE$122
- ABILIFY ASIMTUFII$115
- ABILIFY MAINTENA$115
How this compares
$129,485 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluphenazine Hcl | 32 | $10,084 |
| Lurasidone Hcl | 17 | $6,925 |
| Haloperidol | 26 | $1,861 |
| Fluphenazine Decanoate | 17 | $1,782 |
| Divalproex Sodium | 27 | $1,412 |
| Quetiapine Fumarate | 54 | $1,181 |
| Carbamazepine | 12 | $947 |
| Benztropine Mesylate | 41 | $647 |
| Olanzapine | 22 | $567 |
| Haloperidol Decanoate | 12 | $549 |
| Lorazepam | 51 | $497 |
| Aripiprazole | 12 | $438 |
| Hydroxyzine Pamoate | 36 | $362 |
| Risperidone | 15 | $337 |
| Trazodone Hcl | 35 | $308 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Silvia Silva-DulucMiami$11.7M
- Patricia JunqueraMiami$10.8M
- Evelio SosaMiami$6.9M
- Mario CuervoMiami$6.7M
- Emelina ArochaMiami$4.9M
- Maria RodilMiami$4.5M
- Marc AgroninMiami$4M
- Nancy Navarro-GonzalezMiami$2.6M
- Francisco RicartMiami$2.6M
- Durim BozhdarajMiami$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.